Primarily from the perspective of psychopharmacology, schizophrenic symptom
atology has recently been dichotomized into "plus" and "minus" symptoms, al
though the role of cognitive dysfunctions has been regarded as particularly
important for the diagnosis since the time of Eugen Bleuler. Many studies
show that schizophrenic patients suffer consistently from cognitive dysfunc
tion. Among these, are impairments of attention and memory functions as wel
l as executive functions such as planning and problem solving. These impair
ments are stable or progressive and often continue into the remission phase
of schizophrenia and impair both social integration as well as occupationa
l performance. In this overview, research results on cognitive dysfunction
in patients with schizophrenic illnesses and their relation to psychosocial
disabilities are described first. The therapeutic value and possible clini
cal-practice implications of atypical anti-psychotics and various cognitive
therapy methods are then presented. Methodological weaknesses and open que
stions, both pharmacological and with regard to cognitive interventions, ar
e discussed.